aMost modern targeted therapies such as gleevec, herceptin and rituximab are even more likely to fail in these subcutaneous xenograft animal models. Neither negative (exhibits efficacy in human but not in mice) nor positive (exhibits efficacy in mice but not in human) predictive value of these ...